An estriol test in pregnancy usually measures unconjugated estriol, or uE3, as one component of second-trimester prenatal screening. Estriol is an estrogen produced through cooperation between the fetal adrenal glands, fetal liver, and placenta. Because several parts of the fetoplacental unit contribute to its production, abnormal concentrations can occur with chromosome conditions, inaccurate pregnancy dating, fetal disorders, or placental problems. The result is not diagnostic on its own. Laboratories convert uE3 into a multiple of the median and combine it with maternal age, gestational age, AFP, hCG, and inhibin A to calculate screening risk. Low uE3 is part of characteristic patterns associated with trisomy 21 and trisomy 18, but most low results do not identify a single cause. Very low values may prompt review for rare steroid-production disorders or fetal compromise. Modern ultrasound, cell-free DNA screening, and diagnostic testing provide more direct information than isolated estriol testing.
- Unconjugated estriol is usually measured between 15 and 22 weeks as part of a quad screen, not as a stand-alone routine test.
- Results are reported as multiples of the median because raw concentrations change substantially with gestational age.
- Low uE3 can contribute to increased screening risk for trisomy 21 or trisomy 18, but it does not diagnose either condition.
- Extremely low uE3 may be linked to incorrect dates, fetal demise, steroid sulfatase deficiency, Smith-Lemli-Opitz syndrome, or placental-fetal dysfunction.
- A normal estriol result does not guarantee normal chromosomes, anatomy, growth, or placental function.
- Follow-up depends on the complete screening pattern, ultrasound findings, prior testing, and personal preferences.
Table of Contents
- What Estriol Is
- Why Estriol Is Tested
- Timing, Preparation, and Reporting
- How to Interpret Low Estriol
- High and Normal Estriol Results
- Estriol in the Quad Screen
- Placenta Health and Fetal Well-Being
- Follow-Up After an Abnormal Result
What Estriol Is
Estriol, also called E3, is one of the main estrogens. In nonpregnant people it circulates at low concentrations. During pregnancy it becomes the most abundant estrogen by production volume, although estradiol has stronger biological activity at many receptors.
Pregnancy estriol production depends on a three-part pathway:
- The fetal adrenal glands produce dehydroepiandrosterone sulfate, or DHEA-S.
- The fetal liver modifies much of that precursor, including hydroxylation that favors estriol production.
- The placenta removes sulfate groups and converts the precursor into estriol.
The placenta then releases estriol into maternal circulation. Much of it is rapidly conjugated in the liver, meaning it is chemically attached to sulfate or glucuronide groups. The fraction that remains unconjugated is called uE3 and is the form used in most second-trimester serum screening.
This pathway explains why low uE3 can reflect more than placental function. Reduced fetal adrenal precursor production, impaired fetal liver metabolism, placental enzyme problems, or loss of fetal well-being may all reduce the final concentration.
Estriol should not be confused with estradiol. An estradiol pregnancy test is more likely to be used in fertility monitoring or endocrine assessment. Estriol is primarily a prenatal screening analyte.
Urinary estriol was historically measured repeatedly to monitor high-risk pregnancies. That practice has largely been replaced by ultrasound, Doppler assessment, fetal movement monitoring, nonstress testing, and biophysical profiles because estriol varies and lacks sufficient accuracy as a stand-alone surveillance tool.
Why Estriol Is Tested
The most common reason is inclusion in a second-trimester quad screen. The panel estimates the chance of certain fetal chromosome conditions and open neural tube defects by combining four maternal serum markers:
- Alpha-fetoprotein, or AFP
- hCG
- Unconjugated estriol, or uE3
- Inhibin A
Estriol may also be reviewed after an unexpectedly low value on a prior screen, when a laboratory identifies an unusually extreme result, or during specialist evaluation of a suspected fetal steroid disorder.
The test is a screening test, which means it estimates probability. It does not examine fetal chromosomes and cannot confirm a diagnosis. A screen-positive result may occur in a chromosomally typical pregnancy, while a screen-negative result leaves residual risk.
The quad screen remains useful for people who first enter prenatal care in the second trimester, do not have access to cell-free DNA screening, or choose serum screening. It can also provide AFP-based information about open neural tube defects, which cell-free DNA screening does not evaluate.
Estriol should not be ordered casually as a “placenta health” number. If concern involves fetal growth restriction, preeclampsia, reduced fetal movement, or placental insufficiency, clinical care depends on targeted ultrasound and maternal-fetal assessment rather than a single uE3 value.
Timing, Preparation, and Reporting
Second-trimester serum screening is generally performed between 15 and 22 weeks of gestation. Many programs prefer approximately 16–18 weeks because dating is established and there is time for follow-up. Exact windows vary by laboratory and region.
No fasting is usually required. A blood sample is drawn from a vein. The laboratory needs accurate information because the risk calculation is adjusted for factors that affect marker concentrations:
- Gestational age
- Maternal age
- Weight
- Diabetes status and insulin use
- Singleton or multiple gestation
- Race or ethnicity in programs that still use such adjustments
- Smoking status in some models
- Conception through assisted reproduction
- Prior affected pregnancy
Gestational age has a particularly large effect. Estriol normally rises as pregnancy advances. A dating error of even one or two weeks can make a normal raw value appear abnormally low. Ultrasound dating may lead the laboratory to recalculate the result.
Raw uE3 may be reported in ng/mL or nmol/L, but clinical interpretation usually relies on the multiple of the median, abbreviated MoM. A value of 1.0 MoM equals the median for a pregnancy with the same gestational age and adjustment factors. A value of 0.5 MoM is half that median.
There is no universal stand-alone normal cutoff. Laboratories use their own algorithms and combine all markers into a risk estimate such as 1 in 100, 1 in 500, or screen positive/negative based on a program threshold.
Biotin and other assay-interfering substances may affect some platforms. Tell the laboratory about high-dose supplements and medications. A routine prenatal vitamin usually does not require stopping unless the laboratory or clinician specifically advises it.
How to Interpret Low Estriol
Low uE3 is a finding, not a diagnosis. The degree of reduction and the other screening markers shape its meaning.
Common or important explanations include:
- Pregnancy is earlier than estimated
- A laboratory or data-entry error affected the calculation
- Trisomy 21, where uE3 is often reduced along with low AFP and high hCG and inhibin A
- Trisomy 18, where uE3, AFP, and hCG are often all reduced
- Fetal growth restriction or placental dysfunction
- Fetal demise
- Steroid sulfatase deficiency, often associated with X-linked ichthyosis
- Smith-Lemli-Opitz syndrome, a rare cholesterol-synthesis disorder
- Fetal adrenal hypoplasia or impaired steroid precursor production
- Severe fetal liver dysfunction
A mildly low result is much more common than an extremely low or undetectable value. Mild reductions often lead to a recalculated screening risk rather than a separate diagnosis. Very low values deserve closer review because rare metabolic or steroid disorders become more relevant.
Steroid sulfatase deficiency reduces the placenta’s ability to convert sulfated precursors into estrogens. Pregnancies may otherwise appear normal, and affected male infants can later develop ichthyosis, a dry scaling skin condition. Low estriol can also be associated with prolonged pregnancy or difficulty with labor in some cases, although management is individualized.
Smith-Lemli-Opitz syndrome can produce very low uE3 because the fetus cannot synthesize cholesterol normally. Ultrasound may show growth restriction or structural anomalies, but findings vary. Diagnostic evaluation may include genetic testing or measurement of sterol metabolites under specialist guidance.
A low result should never be interpreted without first confirming gestational age and the complete marker pattern. The same uE3 value can carry different implications when AFP and hCG are high, low, or normal.
High and Normal Estriol Results
High uE3 is generally less specific and less clinically concerning than low uE3. It may reflect:
- Pregnancy being further along than estimated
- Multiple gestation
- Individual biological variation
- Differences in maternal metabolism
- Assay variation
High estriol alone is not a recognized diagnosis of placental overactivity and usually does not require treatment. It can influence the combined screening calculation, but other markers and maternal data remain more important.
A normal uE3 result means the concentration is near the expected median after adjustments. It lowers concern within the screening model but does not rule out chromosome conditions, genetic disorders, structural abnormalities, placental insufficiency, or future pregnancy complications.
Screening sensitivity is never 100%. A fetus with trisomy 21 may have an atypical marker pattern, and most conditions that can affect pregnancy are not included in the test. Every pregnancy should still receive the recommended anatomy ultrasound, usually around 18–22 weeks.
A normal result also does not serve as ongoing evidence of fetal well-being later in pregnancy. Estriol changes over time, and one second-trimester sample cannot predict all later placental events.
Estriol in the Quad Screen
The quad screen recognizes patterns rather than treating each analyte independently.
| Condition or outcome | AFP | hCG | uE3 | Inhibin A |
|---|---|---|---|---|
| Trisomy 21 | Lower | Higher | Lower | Higher |
| Trisomy 18 | Lower | Lower | Lower | Often normal |
| Open neural tube defect | Higher | Not defining | Not defining | Not defining |
These directional patterns are averages. The laboratory combines exact MoM values with maternal age and other variables to estimate risk. A result above a program’s cutoff is called screen positive or high risk. It does not mean the fetus definitely has the condition.
The quad screen generally detects fewer trisomy 21 pregnancies and has more false-positive results than cell-free DNA screening. However, it remains an established option and provides AFP information about neural tube defects.
Multiple screening tests should not be layered without a plan. For example, performing separate independent serum screens can increase the chance of a false positive. A clinician or genetic counselor can explain whether an integrated, sequential, cell-free DNA, or diagnostic pathway best fits the pregnancy.
Placenta Health and Fetal Well-Being
Estriol biology makes it tempting to view uE3 as a direct placental health gauge. In practice, the relationship is too complex for a single measurement to function that way. The level depends on fetal adrenal output, fetal liver conversion, placental enzymes, maternal clearance, gestational age, and assay performance.
Low second-trimester serum markers, including uE3, may be associated with later growth restriction, preeclampsia, preterm birth, or stillbirth at a population level. The predictive value for an individual pregnancy is limited. Many people with an abnormal analyte have uncomplicated outcomes, and many placental complications occur after normal screening.
When an isolated abnormal analyte is associated with placental risk, the care team may review whether additional growth ultrasounds or surveillance are appropriate. Decisions depend on how extreme the result is, whether other markers are abnormal, maternal risk factors, and local guidance.
Fetal well-being later in pregnancy is assessed more directly through fetal movement, growth ultrasound, Doppler flow, amniotic fluid, nonstress testing, and biophysical profile. A historical uE3 value can add context but should not delay evaluation of reduced fetal movement or maternal symptoms.
Follow-Up After an Abnormal Result
The first step is to verify the report. The clinician checks gestational age, maternal data, plurality, and whether the result is part of a complete screen. Recalculation may be possible when dates or demographic information were wrong.
Depending on the result, follow-up can include:
- Detailed ultrasound to confirm dates and examine fetal anatomy
- Genetic counseling to explain the estimated risk and options
- Cell-free DNA screening as a more accurate secondary screen in selected situations
- Chorionic villus sampling or amniocentesis for diagnostic chromosome testing
- Targeted genetic or biochemical testing when uE3 is extremely low
- Serial growth ultrasound when placental risk is a concern
Cell-free DNA is still screening, not diagnosis. A high-risk serum result followed by low-risk cell-free DNA substantially lowers risk but may not evaluate every condition suggested by an extreme estriol result. Diagnostic testing provides the clearest chromosome answer.
Seek prompt maternity assessment for vaginal bleeding, leaking fluid, severe abdominal pain, severe headache, visual changes, sudden swelling, or later in pregnancy, reduced fetal movement. Those symptoms require clinical evaluation rather than repeat estriol testing.
Estriol exists in several forms, and the distinction matters. Prenatal serum screening usually measures unconjugated estriol, abbreviated uE3. Other laboratory tests may measure total estriol, which includes conjugated metabolites, or urinary estriol. These assays have different units, reference intervals, and purposes. A uE3 multiple of the median from a quad screen cannot be compared directly with a raw total-estriol concentration.
The fetoplacental pathway explains why uE3 is a useful but nonspecific marker. Precursors are generated largely by the fetal adrenal glands, modified by the fetal liver, and converted by the placenta into estriol. A lower result can therefore reflect gestational dating, fetal precursor production, placental enzyme activity, or assay and adjustment factors. It does not isolate one organ as the cause.
In second-trimester chromosome screening, low uE3 contributes to patterns for trisomy 21 and trisomy 18. The laboratory combines it with AFP, hCG, inhibin A, maternal age, gestational age, and other variables. The final probability is the result that guides counseling. An isolated low uE3 does not diagnose a trisomy, and a normal uE3 does not exclude one.
Markedly low or undetectable uE3 can occasionally signal conditions beyond the common trisomies. Examples discussed in specialist evaluation include steroid sulfatase deficiency, which can be associated with X-linked ichthyosis, and Smith–Lemli–Opitz syndrome, a rare cholesterol-synthesis disorder. Placental sulfatase deficiency may also be associated with delayed labor. These conditions are uncommon, and the result requires confirmation, detailed ultrasound review, family history, and genetic counseling rather than assumption.
Dating and data quality should be checked first. Because uE3 changes with gestation, an incorrect due date can shift the MoM. Maternal weight, diabetes, smoking, twins, donor egg, assisted reproduction, and a vanishing twin may affect the calculation or its reliability. Recalculation with corrected information is often more useful than repeating the analyte without context.
For suspected fetal or placental problems later in pregnancy, estriol has largely been replaced by more direct tools. Serial maternal estriol testing has not become a standard method for monitoring fetal well-being in routine care. Fetal growth ultrasound, amniotic fluid assessment, Doppler studies, nonstress testing, biophysical profile, and maternal clinical assessment provide more actionable information.
A high estriol value is usually less significant in prenatal screening than a low value. It may reflect normal variation, dating, multiple gestation, or assay factors. It does not prove superior placental function or predict an easier labor.
When a report flags uE3, patients should ask whether the flag changed the overall chromosome-risk calculation, whether the value is mildly low or extremely low, and whether ultrasound findings support concern. If the combined risk is positive, options include cell-free DNA screening in selected circumstances or diagnostic amniocentesis. If uE3 is extremely low despite a low common-trisomy risk, genetics consultation may address rarer explanations.
The appropriate response is proportional. A modest isolated reduction with correct dates and a reassuring integrated screen may need no special action beyond routine anatomy ultrasound. An extreme value, abnormal ultrasound, relevant family history, or multiple abnormal markers warrants more detailed evaluation. The laboratory number alone cannot determine prognosis.
Patients should seek direct care for bleeding, severe abdominal pain, fluid leakage, contractions, reduced fetal movement, severe headache, visual changes, or other concerning symptoms. Maternal estriol is not an emergency triage test and should never delay assessment.
Genetic counseling after very low uE3 may include a three-generation family history, review of fetal sex, targeted ultrasound, and discussion of diagnostic testing. When steroid sulfatase deficiency is suspected in a male fetus, testing options may involve chromosome microarray or targeted analysis depending on the clinical setting. When Smith–Lemli–Opitz syndrome is a concern, ultrasound findings, parental carrier testing, and biochemical or molecular diagnosis may be considered. These pathways are specialist decisions; the analyte alone is not enough.
The laboratory should also be contacted when the value is extremely low because preanalytic and analytic issues are possible. Confirm that the sample was collected within the accepted gestational window, that the correct patient and pregnancy data were entered, and that the result was not affected by a reporting or unit error. A repeat sample may be appropriate if the laboratory recommends it, but repetition should not delay counseling or imaging when the risk calculation is high.
Estriol levels are not a target that can be raised through diet or over-the-counter hormone products. The number reflects a complex pathway, and unregulated supplements may expose the pregnancy to unknown ingredients. Treatment is directed at a diagnosed condition or at pregnancy surveillance, not at normalizing uE3.
For patients with a low integrated screen risk and a normal anatomy scan, the residual meaning of mildly low uE3 may be limited. The obstetric team may document the result and continue routine care, while an extreme isolated reduction may justify a different plan. The magnitude, the rest of the marker profile, ultrasound, and history determine the response.
Reports may use the phrase “screen negative” even when one marker is outside its median range. This means the combined probability stayed below the program cutoff; it does not mean every analyte was average. Conversely, a screen-positive result can occur with a modest uE3 change when age, AFP, hCG, inhibin A, or ultrasound shifts the total risk. The condition-specific probability, rather than the flag beside uE3, should anchor counseling. Patients should retain a copy of the full report because the MoM, dating, and adjustment details may be needed by genetics or maternal-fetal medicine.
The screening laboratory’s comment section may contain the most important information: whether the sample was accepted, which adjustments were applied, and whether follow-up is recommended. Reading only the analyte table can miss those qualifications.
If diagnostic testing is declined, the care team can still offer detailed ultrasound and individualized monitoring while respecting the patient’s preferences. Declining amniocentesis does not mean declining all information or prenatal support.
References
- Prenatal Genetic Screening 2025 (Review)
- Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the Placenta 2023 (Review)
- Performance of Serum Quad Test in Screening for Fetal Down Syndrome in a Large-Scale Unselected Population in a Developing Country 2023 (Study)
- Clinical Assessment of Fetal Well-Being and Fetal Safety Indicators 2022 (Review)
- How to Manage Low Estriol Levels in Pregnancies, One Center Experience 2022 (Study)
Disclaimer
Estriol is a screening marker and cannot diagnose a fetal chromosome condition, genetic disorder, or placental problem by itself. Results require review with the full panel, accurate dating, ultrasound, and appropriate counseling. Contact a maternity professional promptly for concerning symptoms or reduced fetal movement.
